LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$30.17 USD
-0.31 (-1.02%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $29.85 -0.32 (-1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LENZ 30.17 -0.31(-1.02%)
Will LENZ be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LENZ based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LENZ
LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss
LENZ Therapeutics, Inc. (LENZ) is a Great Momentum Stock: Should You Buy?
LENZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Does LENZ Therapeutics, Inc. (LENZ) Have the Potential to Rally 30.86% as Wall Street Analysts Expect?
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know
Other News for LENZ
Lenz Therapeutics (LENZ) Shares Cross Below 200 DMA
Lenz Therapeutics (LENZ) Target Price Hiked Following FDA Approval
Lenz Therapeutics price target raised by $9 at BofA, here's why
Lenz Therapeutics (LENZ) Sees Raised Price Target After FDA Approval
Lenz Therapeutics price target raised by $8 at H.C. Wainwright, here's why